The "Checkpoint Inhibitor Refractory Cancer Drugs Market – Growth, Share, Opportunities & Competitive Analysis, 2025 – 2032" report has been added to the Credence Research Inc. offering.

Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026U.S. Food and Drug ...

The "Checkpoint Inhibitor Refractory Cancer Drugs Market - Growth, Share, Opportunities & Competitive Analysis, 2025 - 2032" report has been added to the ...

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), ...

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data ...

Ipsen initiated an immediate, worldwide withdrawal of the EZH2 inhibitor tazemetostat across follicular lymphoma and epithelioid sarcoma due to emerging safety signals. An independent data monitoring ...

Thomas Smith Leerink Partners LLC, Research Division. Good morning, everyone. Thanks for joining us here at the Leerink Partners Global Healthcare Conference. My name is Tom Smith ...

Ipsen is withdrawing tazemetostat from all markets following signals of secondary hematologic malignancies observed in SYMPHONY-1 evaluating tazemetostat plus lenalidomide/rituximab versus ...

C4 Therapeutics delivered strong 4Q25 results, with revenue up 111.5% YoY and operating expenses tightly controlled. Click for my latest analysis of CCCC stock.

MiNK Therapeutics Inc. INKT shares are up on Tuesday as the company has announced a strategic collaboration with C-Further to develop a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric ...

Radiomics extracts quantitative data from medical images, but its role in predicting deterioration after traumatic brain ...

The collaboration brings together Scipher Medicine’s expertise in precision medicine and molecular patient stratification with Senelix’s therapeutic development capabilities to accelerate the ...